Elanco Acquires Arantana Therapeutics

Elanco Animal Health have acquired Arantana, a pet company that focuses on developing innovative therapeutics for dogs and cats.
The acquisition allows Elanco to further develop Arantana’s first of its kind canine product Galliprant® (designed for dogs with osteoarthritis) and which Elanco have had exclusive right to since 2016. It also adds two additional products to their portfolio; Entyce® (FDA Approved therapeutic to stimulate dogs appetites) and Nocita® (local anaesthetic that gives 72 hours post-operative pain relief for dogs and cats). Arantana’s pipeline in research and development will also contribute to Elanco’s efforts to sustain novel and innovative companion therapeutics.
“This deal furthers our IPP strategy and allows us to continue to bring great value and our customers,” comments Jeff Simmons, president and chief executive officer of Elanco. “Arantana’s current portfolio and pipeline complements our field presence and allows us to capitalise on new opportunities that arise with our existing pet therapy brands.”